TSHA News and Press, Taysha Gene Therapies Inc. From 05/13/24

2024-05-13 17:35:36 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it...

RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support t...

2024-04-12 11:34:12 ET More on S&P 500 Index: Sticking With The More Optimistic View Where We Stand Sorry Campers, The Fed Is Not Riding To The Rescue Nasdaq, S&P, Dow slip as major banks kick off earnings season Nasdaq, S&P climb, Dow end...

2024-04-09 15:16:37 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-04-09 10:00:07 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Well...

2024-04-09 05:00:04 ET Christopher Raymond from Raymond James issued a price target of $9.00 for TSHA on 2024-04-09 03:56:00. The adjusted price target was set to $9.00. At the time of the announcement, TSHA was trading at $2.68. The overall price target consensus is at ...

2024-03-20 12:38:33 ET There was some pretty substantial news coming out of Dallas, TX this morning after a %Biotech company shared initial clinical data from the first pediatric patient from the REVEAL Phase ½ adolescent and adult trial of TSHA-102, an investigational gene therapy...

2024-03-20 12:30:27 ET Summary Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of TSHA-102 treating pediatric patients with Rett Sy...

2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...